Industry Overview

India DNA Vaccine Market was valued at $27.5 million in 2025 and is projected to reach $41.6 million by 2035, growing at a CAGR of 4.3% during the forecast period (2026–2035). The market is growing due to sustained advancements in plasmid DNA vaccine technology and increasing investment in next-generation immunization platforms. Continuous improvements in plasmid design, vector stability, and large-scale manufacturing processes have enhanced antigen expression efficiency and improved the feasibility of both human and animal DNA vaccines. At the same time, progress in plasmid DNA delivery technologies, including electroporation and needle-free systems, has strengthened immunogenic response and expanded clinical applicability across oncology and infectious disease indications. These technological refinements are supported by rising research funding and collaborative development programs aimed at addressing unmet therapeutic needs and emerging pathogens.

Market Dynamics

Increasing Focus on Indigenous Vaccine Innovation and Platform Self-Reliance

The India DNA Vaccine market is witnessing structured growth due to a stronger emphasis on indigenous vaccine research and platform independence. Public health priorities and pandemic preparedness strategies have encouraged domestic development of plasmid DNA vaccine platforms to reduce reliance on imported technologies. This shift is supported by expanded funding for translational research and infrastructure upgrades in biologics manufacturing facilities. As a result, companies are investing in scalable plasmid production capabilities and in-house delivery technologies tailored to local regulatory and epidemiological requirements.

Expansion of DNA Vaccine Applications in Oncology and Veterinary Segments

Another emerging trend shaping the India DNA vaccine market is the diversification of applications beyond infectious diseases into oncology and veterinary use. DNA vaccine platforms offer flexibility in encoding tumor-specific antigens, making them attractive for personalized and therapeutic cancer strategies under development in India. Simultaneously, the veterinary sector is exploring animal DNA vaccines to address livestock productivity and disease management, particularly in high-value poultry and cattle segments. The adaptability of plasmid constructs allows faster antigen customization compared to conventional vaccine platforms, supporting pipeline growth in both human and animal categories.

Market Segmentation

• Based on the type, the market is segmented into animal DNA vaccine, and human DNA vaccine.
• Based on the technology, the market is segmented into plasmid DNA vaccines technology, and plasmid DNA delivery technology.
• Based on the application, the market is segmented into oncology, infectious diseases, and others.

Human DNA Vaccines Drive Clinical and Infectious Disease Growth

The human DNA vaccine segment represents a leading component of the India DNA Vaccine market, driven primarily by its expanding role in infectious disease prevention and therapeutic research. The regulatory authorization of plasmid DNA-based vaccines in India has strengthened confidence in this platform and demonstrated commercial viability. Increasing preparedness for emerging pathogens has further encouraged investment in domestic plasmid vaccine infrastructure. Improvements in plasmid construct design and stability are enhancing immune response consistency across clinical programs. These combined factors position the segment as a core contributor to overall market growth.

Plasmid DNA Delivery Technology Strengthens Vaccine Efficacy

The plasmid DNA delivery technology segment is emerging as a significant enabler within the India DNA Vaccine market. Efficient intracellular delivery remains essential for achieving adequate antigen expression, placing emphasis on electroporation and needle-free injection systems. Ongoing refinement of delivery devices has improved dose accuracy and immunogenic performance, addressing earlier platform limitations. Indian developers are increasingly integrating advanced delivery technologies into both human and animal DNA vaccine programs. As delivery effectiveness directly impacts clinical outcomes and commercialization prospects, this segment continues to gain strategic importance in market expansion.

Market Players Outlook

The major companies operating in the India DNA vaccine market include Bharat Biotech International Ltd., Inovio Pharmaceuticals, Inc., Recipharm AB, VGXI, Inc., Zydus Lifesciences Ltd, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In February 2022, Zydus began supplying its Covid-19 vaccine ZyCoV-D to the Indian government from its new Vaccine Technology Excellence Centre in Ahmedabad.
• In August 2021, Zydus Cadila received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first Plasmid DNA Vaccine for COVID-19.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the India DNA vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.